Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

Specifically blocking more than one oncogenic pathway simultaneously in a Cancer cell with a combination of different drugs is the mainstay of the majority of Cancer treatments. Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients. In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of molecule based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat. Both series of compounds had examples with low nanomolar JAK2 and HDAC1/6 inhibition. In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity. The observed potency is explained through molecular docking studies of all three Enzymes. One example, 69c had 16-25 fold selectivity against the three Other JAK-family proteins JAK1, JAK3 and Tyk2. A number of compounds had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematological cell lines with the most potent compound, 45h, having a cellular IC₅₀ of 70 nM against the multiple myeloma cell line KMS-12-BM. Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated. Evidence of Apoptosis with two compounds in 4 sold tumor cell lines is also presented.

HDAC inhibitor; JAK/HDAC dual inhibitor; JAK2 inhibitor; Multicomponent ligand.